|
News
and News Archive
Research
Advances
is located on the home page of our web site. We will continue to
keep global NEWS posted to this site for reference. Please make sure
that you are always referring to current information when making
health care decisions or when educating others about hepatitis.
For more News and
Features, see our homepage
here.
Our News Archives can
be viewed
here.
Features Continued from Home
Page...
Continued from Home
Page...
HFI AWARDED $20,000 FROM ABBOTT FUND
Each year, more that 600,000
American become newly infected with viral hepatitis yet many of
these cases go unreported. Often called the "silent
epidemic", many individuals infected with viral hepatitis have
not signs or symptoms of the disease until chronic infection or
chronic liver disease has developed. Education and outreach
are key to combat these diseases that affect over 500 million people
around the world.
"Often
it is not the doctor, but a nurse or physician assistant that spends
more time with a patient during an office visit", said Thelma
King Thiel, Chairman and CEO, HFI. "That is why it is so
important for HFI to offer our Foundation for Decision Making
train-the-trainer programs which give health care providers advice
on how to best educate patients about liver wellness and risky
behaviors that could lead to a viral hepatitis infection."
Hepatitis
literally means inflammation of the liver and is caused by infection
with one of five viruses, hepatitis A, B, C, D, or E. Two of the
most common infections are the hepatitis B virus (HBV) and the
hepatitis C virus (HCV). Both infections can be transmitted from
high-risk behaviors such as having sex with multiple partners or an
infected person without a condom, or from sharing drugs, needles or
drug paraphernalia when "shooting" drugs.
HFI seeks
to raise awareness of viral hepatitis by educating the public and
hepatitis patients about prevention, diagnosis and treatment of
viral hepatitis. For more information about liver wellness or viral
hepatitis, visit: www.hepatitisfoundation.org.
Continued from Home
Page...
SAMHSA GRANTEES APPLAUD LIVER WELLNESS APPROACH
Invited by Claudia Richards,
Chief, HIV Behavioral Health Issues Branch, at the Center for
Substance Abuse Prevention (CSAP), Thelma King Thiel, HFI’s CEO,
addressed one hundred eighty of CSAP grant recipients at a two day
conference in Washington DC, January 18th and 19th. Making liver
wellness "come alive" through humor and memorable analogies, Thiel
had her audience's undivided attention.
“I learned so much in just a few minutes,” commented Craig
McGuire, M.S., a consultant conducting the evaluation of a SAMHSA
project in
Kentucky.
“Your upbeat approach is sorely needed to help our clients change
their behaviors. We look forward to working with you,” said L.
Elaine Sutton Mbionwu, CEO of The National Re-Entry Resource Center
in
Atlanta ,
GA.
Plans are already underway to provide HFI’s Foundation for
Decision Making Training program for the Latin American Youth Center
staff and constituents in
Washington ,
DC
. The Orange Bar Foundation in
California
collaborated with HFI to address liver wellness and hepatitis in
their program responsibilities. For more information about HFI’s
Training programs, call 800-891-0707
NEWS IN REVIEW
Australia's
Therapeutic Goods Administration has taken a tough stance over the
safety record of black cohosh, requiring that over the counter and
alternative medicines containing the herbal must carry a warning for
potential harm to the liver.
For more information, click here...
Anady's Pharmaceuticals, Inc. announced
robust viral load reduction successfully achieved in Phase II clinical
trial of ANA380 in Lamivudine-resistant hepatitis B patients. For more information, click here...
A
landmark study by Florida State
University biologists could bolster the development of anti-viral
therapy for hepatitis C by the discovery of the mechanism that
inhibits HCV replication. For
more information, click here...
Nabi Pharmaceuticals has received approval from the FDA to move its
new Civacir product to a "fast track" status. Civicar is an
antibody designed to stop hepatitis C from re-infecting liver
transplants. For more information, click here...
2004/2005 News Archive
For a copy of News from
2004/2005, click here.
2006 News Archive
For a copy of News from 2006,
click here.
Scroll to Top or
Back to Home Page
the good we do | living
with hepatitis | news
& research | support
donate | contact
us | site map |
home
nnac | online
learning center | subscribe
to our newsletter
| disclaimer | privacy
|